SEC Form 4 · accession 0001193125-26-274275
IRONWOOD PHARMACEUTICALS INC · IRWD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Julie McHugh
Director
Period of report
Jun 16, 2026
Accepted (ET)
Jun 17, 2026 · 4:41 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001446847
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common Stock | Jun 16, 2026 | A | 63,481 | $0.00 | A | 272,320 | D | |
| Class A Common StockF3 | Jun 16, 2026 | S | 21,571 | $3.73 | D | 250,749 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year.
- F2This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F3The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.66 to $3.78, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.